Overall Survival – Talk Bio

NeOnc Technologies Reports Updated Clinical Results for Intranasal NEO100

3 weeks ago talkbio0Tagged Central Nervous System Neoplasms, clinical results, Compassionate Use, Intranasal approach, NEO100, NeOnc Technologies, NTHI, Overall Survival, Phase 1/2a trial, radiographic remission, recurrent astrocytoma, World Health Organization

NeOnc Technologies; NTHI; NEO100; intranasal NEO100; updated clinical results; recurrent astrocytoma; WHO Grade III/IV; radiographic remission; overall survival; compassionate use; Phase 1/2a trial; CNS cancers

‘Au Revoir TIGIT’: Gilead, Arcus Cut Gastro Cancer Drug After Late-Stage Failure

3 weeks ago talkbio0Tagged Arcus Biosciences, casdatifan, domvanalimab, EDGE-Gastric, Esophageal Neoplasms, Failure (biologic function), Gilead Sciences, immuno-oncology, Malignant neoplasm of stomach, nivolumab, Opdivo, Overall Survival, Phase 3 trial, STAR-221, TIGIT gene, zimberelimab

domvanalimab; TIGIT; Gilead Sciences; Arcus Biosciences; STAR-221; gastric cancer; esophageal cancer; zimberelimab; Opdivo (nivolumab); Phase 3 trial failure; overall survival; casdatifan; immuno-oncology; EDGE-Gastric

FDA Signals Higher Efficacy Bar for New CAR‑T Cancer Therapies

1 month ago talkbio0Tagged CAR-T, Cells, Chimeric Antigen Receptor T-Cell Therapy, gene therapy, Hematologic Neoplasms, Neoplasms, Overall Survival, Randomized Controlled Trials as Topic, regulatory standards, superiority trials, United States Food and Drug Administration

FDA; CAR-T; chimeric antigen receptor T-cell therapy; oncology; regulatory standards; superiority trials; randomized controlled trials; overall survival; hematologic malignancies; cell and gene therapy

Imvax Shares Positive Phase 2b Data for IGV-001 Glioblastoma Treatment and Plans FDA Meeting

1 month ago talkbio0Tagged Clinical Trials, Glioblastoma, IGF-1R Antisense Oligodeoxynucleotide-treated Autologous Glioma Cells IGV-001, Immunotherapy, Imvax, meeting, Overall Survival, United States Food and Drug Administration

Imvax; IGV-001; glioblastoma; Phase 2b trial; overall survival; FDA meeting; immunotherapy; clinical trial; glioblastoma treatment

Jazz and Zymeworks Bispecific Antibody Zanidatamab Delivers Practice-Changing Results in Stomach Cancer Study

2 months ago talkbio0Tagged Antibodies, Bispecific, erbB-2 Receptor, gastroesophageal adenocarcinoma, Jazz, Malignant neoplasm of stomach, orphan drug designation, Overall Survival, Pharmacotherapy, Phase 2 trial, Phase 3, practice-changing, Progression-Free Survival, Zanidatamab, Zymeworks

Jazz Pharmaceuticals; Zymeworks; zanidatamab; bispecific antibody; HER2; gastroesophageal adenocarcinoma; stomach cancer; phase 2 trial; phase 3 HERIZON-GEA-01; overall survival; progression-free survival; chemotherapy; practice-changing; Orphan Drug designation

ESMO 2025 KEYNOTE-671 Update: Perioperative Pembrolizumab Reinforces NSCLC Standard

2 months ago talkbio0Tagged ESMO Congress, Event-Free Survival, Immunotherapy, KEYNOTE-671, Keytruda, Non-Small Cell Lung Carcinoma, Overall Survival, pembrolizumab, perioperative, Standard of Care

KEYNOTE-671; pembrolizumab; KEYTRUDA; perioperative immunotherapy; NSCLC; overall survival; event-free survival; ESMO Congress; standard of care

Exelixis’ Kinase Blocker Zanzalintinib Sets New Survival Standard in Third-Line Metastatic Colorectal Cancer, Paving Way for FDA Review

3 months ago talkbio0Tagged Colorectal Carcinoma, Exelixis, kinase inhibitor [EPC], Overall Survival, regorafenib, STELLAR-303 trial, Submission, Tecentriq, Third line treatment, United States Food and Drug Administration, zanzalintinib

Exelixis; zanzalintinib; kinase inhibitor; colorectal cancer; STELLAR-303 trial; Tecentriq; regorafenib; overall survival; third-line therapy; FDA submission

Tecentriq Demonstrates Survival Benefit in ctDNA-Guided Bladder Cancer Treatment at ESMO 2025

3 months ago talkbio0Tagged adjuvant treatment, atezolizumab, ctDNA-guided therapy, Disease-Free Survival, ESMO, genentech, IMvigor011, Malignant neoplasm of urinary bladder, muscle-invasive bladder cancer, Overall Survival, Roche (company), Signatera, Tecentriq

Tecentriq; atezolizumab; ctDNA-guided therapy; IMvigor011; bladder cancer; muscle-invasive bladder cancer; adjuvant treatment; overall survival; disease-free survival; ESMO 2025; Signatera; Genentech; Roche

Merck & Co. Announces Keytruda Achieves First Overall Survival Benefit in Resistant Ovarian Cancer

3 months ago talkbio0Tagged checkpoint inhibitor, Co., KEYNOTE-B96 trial, Keytruda, Merck, ovarian neoplasm, Overall Survival, PD-L1, pembrolizumab, platinum-resistant, Progression-Free Survival

Merck & Co.; Keytruda; pembrolizumab; ovarian cancer; platinum-resistant; overall survival; checkpoint inhibitor; KEYNOTE-B96 trial; progression-free survival; PD-L1

AstraZeneca Furthers Ambition to Redefine Cancer Care with First Data from Four Major Pivotal Trials at ESMO 2025

3 months ago talkbio0Tagged Antibody-Drug Conjugates, AstraZeneca, cancer care, Datopotamab deruxtecan, Datroway, Deruxtecan, durvalumab, Enhertu, ESMO, Imfinzi, Malignant neoplasm of stomach, Malignant neoplasm of urinary bladder, Neoplasms, Overall Survival, trastuzumab, trials, Triple Negative Breast Neoplasms

AstraZeneca; ESMO 2025; cancer care; pivotal trials; oncology; Datopotamab deruxtecan (Datroway); Enhertu (trastuzumab deruxtecan); Imfinzi (durvalumab); triple-negative breast cancer; bladder cancer; gastric cancer; overall survival; antibody-drug conjugates